Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 21Multiple Myeloma 20Neoplasm Metastasis 18Lymphoma 16Leukemia, Myeloid, Acute 15Breast Neoplasms 14Prostatic Neoplasms 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Ovarian Neoplasms 11Melanoma 10Glioma 10Fallopian Tube Neoplasms 10Urinary Bladder Neoplasms 9Pancreatic Neoplasms 9Triple Negative Breast Neoplasms 8Sarcoma 8Carcinoma, Renal Cell 8Medulloblastoma 7Cholangiocarcinoma 7Burkitt Lymphoma 7Small Cell Lung Carcinoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Oropharyngeal Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia, Biphenotypic, Acute 6Glioblastoma 6Endometrial Neoplasms 6Carcinosarcoma 6Uterine Cervical Neoplasms 5

Interventions

Nivolumab 2Ipilimumab 2vedolizumab 1gallium 68 PSMA-11 1fludarabine 1cabozantinib 1aldesleukin 1abiraterone 1abemaciclib 1Therapeutics 1Specimen Handling 1Prednisone 1Prednisolone 1Magnetic Resonance Spectroscopy 1LDP-02 1Interleukin-2 1Infliximab 1Immunoglobulin G 1Geriatric Assessment 1Fulvestrant 1Exercise 1Disulfides 1Cyclophosphamide 1CTLA-4 Antigen 1CT-P13 1Biopsy 1Androgen Antagonists 1Adrenal Cortex Hormones 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urogenital Neoplasms × Specimen Handling × Clear all
NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡